Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955940 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
A Phase 2 study of Breast Cancer and Lung Cancer, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 9
- Study locations
NCT02955940 is a Phase 2 study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT02955940, a Phase 2 study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Regorafenib
- DRUG Ruxolitinib
Study Locations (9)
Other
- Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii - Krakow
- Samodzielny Publiczny Szpital Kliniczny - Lublin
- Instytut Hematologii I Transfuzjologii - Warsaw
Texas
- University of Texas M. D. Anderson Cancer Center - Houston
- Renovatio Clinical Consultants Llc - The Woodlands
California
- UCLA Healthcare Hematology-Oncology - Santa Monica
Kentucky
- University of Louisville - Louisville
New York
- New York Oncology Hematology Pc. - Clifton Park
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955940
The ClinicalTrials.gov registry entry for NCT02955940 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT02955940 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02955940 about?
NCT02955940 is a clinical study titled "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib". The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also ...
What is the current status of trial NCT02955940?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-11-30. Estimated completion is 2027-09-30.
What conditions does trial NCT02955940 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer (CRC).
What interventions are being tested in trial NCT02955940?
The interventions under investigation include: Capecitabine (DRUG), Regorafenib (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02955940?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02955940 being conducted?
This trial has 9 study locations across California, Kentucky, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.